NRX Pharmaceuticals Inc (NRXP)
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead programs include NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being studied in phase 2 for suicidal treatment-resistant bipolar depression with sub-acute suicidal ideation and behavior, and NRX-100, a preservative-free ketamine formulation intended for intravenous infusion and the treatment of suicidal depression. The company has entered into licensing and development arrangements with Alvogen, Inc., Lotus Pharmaceutical Co. Ltd., Apkarian Technologies, Glytech, LLC, and Sarah Herzog Memorial Hospital, and it also has a partnership with neurocare Group AG to support a network of clinics for integrated neuroplastic care. NRx Pharmaceuticals was founded in 2015 and is based in Wilmington, Delaware.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NRXP
|
$3.38
|
1.9% Upside
|
Fair
|
$38.25 1,052.1% Upside
|
Not available
|
Bargain
|
Fair
|
0.0%
|
November 16, 2026
|
41.9x
|
143.6 M
|
116.5 M
|
0.6%
|
86.4%
|
-14.1
|
88.0%
|
